The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST

Thursday, December 01, 2011

Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST11:00 EST Thursday, December 01, 2011TARRYTOWN, N.Y., Dec. 1, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a time change for the Company's presentation at the 2011 Deutsche Bank BioFEST scheduled for Monday, December 5, 2011.  The presentation is scheduled for 1:05 p.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through January 4, 2012.  About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA? (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Michael Aberman, M.D.       Peter DworkinInvestor Relations          Corporate Communications914.847.7799                 914.847.7640michael.aberman@regeneron.com        peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.